John Tavis

New Capabilities

As of September 2026: Independent commentator on the study

A single injection silenced hepatitis B virus in human liver cells and mice by tagging viral DNA with chemical marks instead of cutting it. The therapy, called CRMA-1001, is now in human trials in Hong Kong and New Zealand, with the first participant dosed in January 2026.

Updated Sep 21